Allotype BioDiscovery

Olink and the University of Leeds are proud to announce the launch of Allotype BioDiscovery, a new venture dedicated to advancing precision proteomics and translational research.

Proteomics is taking the breakthroughs of genomics to the next level. As a vital force behind the next wave of scientific discovery, proteomics is transforming our understanding of disease mechanisms, early diagnosis and therapeutic development across many diseases and conditions - accelerating the path to personalized treatment.

Join us for an exclusive in-person event where science meets impact. Explore how affinity-based proteomics is revolutionizing drug discovery, deepening our grasp of complex diseases, and shaping the future of healthcare. Connect with leading experts, see the latest innovations in action, and be part of the conversation that's redefining precision medicine. Come along and learn how to accelerate your proteomic discovery through strategic collaboration between academia, healthcare and drug discovery.